GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (STU:5Y6) » Definitions » 3-Year FCF Growth Rate

Compass Pathways (STU:5Y6) 3-Year FCF Growth Rate : 7.90% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Compass Pathways 3-Year FCF Growth Rate?

Compass Pathways's Free Cash Flow per Share for the three months ended in Jun. 2024 was €-0.47.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 7.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -29.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 6 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Compass Pathways was 7.90% per year. The lowest was -44.50% per year. And the median was -43.60% per year.


Competitive Comparison of Compass Pathways's 3-Year FCF Growth Rate

For the Medical Care Facilities subindustry, Compass Pathways's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compass Pathways's 3-Year FCF Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Compass Pathways's 3-Year FCF Growth Rate falls into.



Compass Pathways 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Compass Pathways  (STU:5Y6) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Compass Pathways 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Compass Pathways's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Compass Pathways Business Description

Traded in Other Exchanges
Address
33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Compass Pathways Headlines

No Headlines